Looking Forward to a Golden Autumn
Welcome to this month's eNews
It is hard to describe the news flow and activity in the Life Sciences sector as anything but an emotional rollercoaster for most in the sector. The worrisome news of large Pharma withdrawing or placing under review R&D investment in the UK, along with continuing news of financing challenges and staff redundancies, has profound implications for many.
There have been some brighter activities too. Deals completed, vacancies advertised, energetic gatherings reminding us that the fundamental strengths of the sector are excellent and unchanged, and developments in how One Nucleus is rolling out evolved support initiatives at this challenging time.
As they say, time waits for no one, and One Nucleus wants to enable its members to be ready to grasp the exciting opportunities that arise in both good and challenging times.
Keeping track of the opportunities available is also a challenge in an era of immense headlines, content, and data arriving by email, social media, and meetings. To address this need, we have introduced the One Nucleus Recap article to our regular eNews. The recap will serve as a reminder of recent sector headlines and the commentary around them, completed deals by companies in the One Nucleus home patch, and reminders of new One Nucleus initiatives you may have missed.
In this issue, readers will be able to click through to a range of articles, along with updates around London Bio-innovation Week plans, the One Nucleus Annual Awards 2026 categories, notes from the September BioWednesday Breakfast, as well as the ABPI report on UK Competitiveness and the report on the European Commission, Heads of Medicines Agencies and EMA on their goals for clinical trials in Europe.
Staying Up-to-date
Remain informed of all One Nucleus updates, disseminate your company’s news, or track the announcements from other members, and make full use of our website, LinkedIn, or X pages. The news stream contains numerous updates from our community. Enjoy the read! Tony Jones
••••••••••••••••••••••••••••••••••••••••
One Nucleus Recap – News You May Have Missed
Tony Jones, CEO of One Nucleus, recaps the news you may have missed and looks ahead at exciting opportunities for the life science ecosystem. Read the article here.
London Bio-innovation Week: 1-5 December 2025: The Next Generation of Conference Collaboration
In December four fully independent events will be co-located in one city of over 1000 collective event attendees active in basic or translational research, collaboration and investment in bio-innovation. Check out the opportunities here.
Securing the Recognition Your Colleagues Deserve
When it comes to a high-quality and competitive landscape such as the Life Sciences sector, the benefits of getting involved in award competitions can be impressive. Find out here why you should enter the One Nucleus Awards 2026.
Scaling Science and Technology Successfully: Insights from the BioWednesday at The Press, Foxton
In September, leaders from across the life sciences industry came together for a One Nucleus BioWednesday Breakfast Session, generously hosted by Mission Street at The Press in Foxton alongside Bidwells. The session explored what it takes for science and technology companies, particularly spin-outs and early-stage ventures, to grow and scale effectively in the UK. Read the key takeaways by Alicia Gailliez, Business Development Manager, One Nucleus.
ABPI Report Sets Out What Needs Addressing to Improve the UK's Competitiveness to Pharma
A new Pharmaceutical Competitiveness Framework from ABPI reveals that the UK is losing the race for investment in R&D, clinical trial delivery, and foreign direct investment due to increasing drags on competitiveness. Read the article here.
New Targets for Clinical Trials in Europe
The European Commission (EC), the Heads of Medicines Agencies (HMA) and EMA have jointly developed two new targets for clinical trials to monitor progress against the ambition to make the European Union (EU) a more attractive destination for clinical research and improve timely access to innovative medicines for patients. Find out more here.
Find out more about BIO Europe Opportunities here
Find out more about Genesis 2025 here
Find out more about the One Nucleus Awards 2026 here
